WO2008081928A1 - ピラゾロピリミジン化合物 - Google Patents

ピラゾロピリミジン化合物 Download PDF

Info

Publication number
WO2008081928A1
WO2008081928A1 PCT/JP2007/075278 JP2007075278W WO2008081928A1 WO 2008081928 A1 WO2008081928 A1 WO 2008081928A1 JP 2007075278 W JP2007075278 W JP 2007075278W WO 2008081928 A1 WO2008081928 A1 WO 2008081928A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolopyrimidine compound
disclosed
pyrazolopyrimidine
arthritides
syk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/075278
Other languages
English (en)
French (fr)
Inventor
Makoto Yagi
Hiroki Umemiya
Hajime Asanuma
Yusuke Oka
Rie Nishikawa
Keishi Hayashi
Takumi Okada
Takanori Shimizu
Shigetada Sasako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Taisho Pharmaceutical Co Ltd
Original Assignee
Nissan Chemical Corp
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp, Taisho Pharmaceutical Co Ltd filed Critical Nissan Chemical Corp
Priority to EP07860481A priority Critical patent/EP2123654A4/en
Priority to US12/521,518 priority patent/US20100298557A1/en
Priority to CA002673965A priority patent/CA2673965A1/en
Priority to KR1020097013434A priority patent/KR20090103897A/ko
Priority to JP2008552181A priority patent/JPWO2008081928A1/ja
Publication of WO2008081928A1 publication Critical patent/WO2008081928A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

【課題】Ｓｙｋ及び／又はＡｂｌ阻害作用に基づいたアレルギー性疾患、自己免疫疾患、関節炎又は癌などの疾病の予防・治療に有用な新規な化合物を提供することである。 【解決手段】 式(I)又は式(III)で表されるピラゾロピリミジン化合物、該化合物の互変異性体、立体異性体若しくはその薬学的に許容される塩又はそれらの溶媒和物を提供する。
PCT/JP2007/075278 2006-12-28 2007-12-28 ピラゾロピリミジン化合物 Ceased WO2008081928A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07860481A EP2123654A4 (en) 2006-12-28 2007-12-28 pyrazolopyrimidine compound
US12/521,518 US20100298557A1 (en) 2006-12-28 2007-12-28 Pyrazolopyrimidine compound
CA002673965A CA2673965A1 (en) 2006-12-28 2007-12-28 Pyrazolopyrimidine compound
KR1020097013434A KR20090103897A (ko) 2006-12-28 2007-12-28 피라졸로피리미딘 화합물
JP2008552181A JPWO2008081928A1 (ja) 2006-12-28 2007-12-28 ピラゾロピリミジン化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-353781 2006-12-28
JP2006353781 2006-12-28

Publications (1)

Publication Number Publication Date
WO2008081928A1 true WO2008081928A1 (ja) 2008-07-10

Family

ID=39588608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/075278 Ceased WO2008081928A1 (ja) 2006-12-28 2007-12-28 ピラゾロピリミジン化合物

Country Status (8)

Country Link
US (1) US20100298557A1 (ja)
EP (1) EP2123654A4 (ja)
JP (1) JPWO2008081928A1 (ja)
KR (1) KR20090103897A (ja)
CN (1) CN101611035A (ja)
CA (1) CA2673965A1 (ja)
RU (1) RU2009128982A (ja)
WO (1) WO2008081928A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026107A1 (en) * 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
WO2012057262A1 (ja) * 2010-10-28 2012-05-03 日本新薬株式会社 ピリジン誘導体及び医薬
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
US8372858B2 (en) 2006-12-08 2013-02-12 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2015529232A (ja) * 2012-09-20 2015-10-05 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピロロピリミジニルアミノ−ベンゾチアゾロン
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
EP2516434B1 (en) 2009-12-23 2015-05-27 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
AU2011323484B2 (en) * 2010-11-01 2016-10-06 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2015021149A1 (en) * 2013-08-06 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ack1/tnk2 tyrosine kinase
TW201625620A (zh) 2014-05-14 2016-07-16 美國科羅拉多州立大學 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
ES2754803T3 (es) * 2015-01-23 2020-04-20 Glaxosmithkline Ip Dev Ltd Derivado de pirazolo[3,4-dpirimidina y su uso para el tratamiento de leishmaniasis
CN107383014B (zh) * 2017-06-21 2019-04-30 南方医科大学 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用
CA3098988A1 (en) 2018-05-02 2019-11-07 Jw Pharmaceutical Corporation Heterocycle derivative
HRP20231310T1 (hr) 2019-05-10 2024-02-02 Deciphera Pharmaceuticals, Llc Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
ES3072710T3 (en) 2019-06-17 2026-07-03 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
CN116023380B (zh) * 2021-10-26 2024-01-23 沈阳药科大学 一类吡唑并嘧啶衍生物及制备方法和应用
CN115368366A (zh) * 2022-08-02 2022-11-22 江苏省中医药研究院 嘧啶并吡唑类化合物及其应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4899194A (ja) 1972-03-03 1973-12-15
WO2000075113A1 (en) 1999-06-09 2000-12-14 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
JP2001501216A (ja) * 1996-10-02 2001-01-30 ノバルティス アクチエンゲゼルシャフト ピリミジン誘導体およびその製造法
WO2001009134A1 (en) 1999-07-30 2001-02-08 Novartis Ag Purine derivatives inhibitors of tyrosine protein kinase syk
WO2001083485A1 (en) 2000-04-28 2001-11-08 Bayer Aktiengesellschaft Imidazopyrimidine derivatives and triazolopyrimidine derivatives
WO2003057695A1 (en) 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
WO2003063794A2 (en) 2002-02-01 2003-08-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
JP2004203748A (ja) 2002-12-24 2004-07-22 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，２−ｃ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
WO2006047256A1 (en) 2004-10-21 2006-05-04 Vertex Pharmaceuticals Incorporated Triazoles useful as inhibitors of protein kinases
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
WO2006093247A1 (ja) 2005-02-28 2006-09-08 Japan Tobacco Inc. Ｓｙｋ阻害活性を有する新規なアミノピリジン化合物
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE541848T1 (de) * 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4899194A (ja) 1972-03-03 1973-12-15
JP2001501216A (ja) * 1996-10-02 2001-01-30 ノバルティス アクチエンゲゼルシャフト ピリミジン誘導体およびその製造法
WO2000075113A1 (en) 1999-06-09 2000-12-14 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
WO2001009134A1 (en) 1999-07-30 2001-02-08 Novartis Ag Purine derivatives inhibitors of tyrosine protein kinase syk
JP2003506375A (ja) * 1999-07-30 2003-02-18 ノバルティス アクチエンゲゼルシャフト チロシンタンパク質キナーゼｓｙｋのプリン誘導体阻害剤
WO2001083485A1 (en) 2000-04-28 2001-11-08 Bayer Aktiengesellschaft Imidazopyrimidine derivatives and triazolopyrimidine derivatives
WO2003057695A1 (en) 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
WO2003063794A2 (en) 2002-02-01 2003-08-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
JP2004203748A (ja) 2002-12-24 2004-07-22 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，２−ｃ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
WO2006047256A1 (en) 2004-10-21 2006-05-04 Vertex Pharmaceuticals Incorporated Triazoles useful as inhibitors of protein kinases
WO2006093247A1 (ja) 2005-02-28 2006-09-08 Japan Tobacco Inc. Ｓｙｋ阻害活性を有する新規なアミノピリジン化合物
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"DESIGN OF PRODRUGS", 1985, ELSEVIER
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 8, 2003, pages 1415
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 13, 2005, pages 4936
CANCER RES., vol. 66, no. 11, 1 June 2006 (2006-06-01), pages 5648 - 5655
CANCER RES., vol. 67, no. 4, 15 February 2007 (2007-02-15), pages 1580 - 1588
J. IMMUNOL., vol. 169, no. 2, 15 July 2002 (2002-07-15), pages 1028 - 1036
J. PHARMACOL. EXP. THER., 31 August 2006 (2006-08-31)
J. PHARMACOL. EXP. THER., vol. 306, no. 3, September 2003 (2003-09-01), pages 1174 - 1181
J. PHARMACOL. EXP. THER., vol. 317, no. 2, May 2006 (2006-05-01), pages 571 - 578
ONCOGENE, vol. 13, no. 12, 19 December 1996 (1996-12-19), pages 2595 - 2605
ONCOGENE, vol. 26, no. 52, 15 November 2007 (2007-11-15), pages 7313 - 7323
PROC. NATL. ACAD. SCI. USA., vol. 101, no. 16, 20 April 2004 (2004-04-20), pages 6158 - 6163
See also references of EP2123654A4

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372858B2 (en) 2006-12-08 2013-02-12 Irm Llc Compounds and compositions as protein kinase inhibitors
US8957081B2 (en) 2006-12-08 2015-02-17 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009026107A1 (en) * 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
WO2012057262A1 (ja) * 2010-10-28 2012-05-03 日本新薬株式会社 ピリジン誘導体及び医薬
CN103298788A (zh) * 2010-10-28 2013-09-11 日本新药株式会社 吡啶衍生物及医药
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
JP2015529232A (ja) * 2012-09-20 2015-10-05 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピロロピリミジニルアミノ−ベンゾチアゾロン
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same

Also Published As

Publication number Publication date
EP2123654A1 (en) 2009-11-25
CA2673965A1 (en) 2008-07-10
JPWO2008081928A1 (ja) 2010-04-30
RU2009128982A (ru) 2011-02-10
EP2123654A4 (en) 2011-05-11
CN101611035A (zh) 2009-12-23
KR20090103897A (ko) 2009-10-01
US20100298557A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
CR20210001A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2)
WO2008076046A8 (en) Novel 2-amino-5, 5-diaryl-imidazol-4-ones
WO2007023382A3 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2006053255A3 (en) Novel betulin derivatives, preparation thereof and use thereof
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
TW200734311A (en) New compounds
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
WO2006020276A3 (en) Antiviral compounds
WO2008142720A3 (en) Quinazolin-oxime derivatives as hsp90 inhibitors
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2007061737A3 (en) FUSED BICYCLIC mTOR INHIBITORS
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
WO2007135527A3 (en) Benzimidazolyl compounds
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
WO2009121033A3 (en) Substituted nitrogen heterocycles and synthesis and uses thereof
WO2008105526A1 (ja) マクロ環状化合物
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2007011760A3 (en) Inhibitors of mitotic kinesin
WO2010144499A3 (en) Urea derivatives as kinase inhibitors
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
WO2005094329A3 (en) Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
WO2008026125A3 (en) Anti cancer use of caffeic acid and derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048889.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860481

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008552181

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 4151/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2673965

Country of ref document: CA

Ref document number: 12521518

Country of ref document: US

Ref document number: 1020097013434

Country of ref document: KR

Ref document number: 2007860481

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009128982

Country of ref document: RU

Kind code of ref document: A